---
document_datetime: 2025-12-02 04:52:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/qinlock.html
document_name: qinlock.html
version: success
processing_time: 0.1196997
conversion_datetime: 2025-12-24 03:21:36.423519
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Qinlock

[RSS](/en/individual-human-medicine.xml/67487)

##### Authorised

This medicine is authorised for use in the European Union

ripretinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Qinlock](#news-on)
- [More information on Qinlock](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Qinlock is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, in adults with advanced disease who have already been treated with three or more medicines of the 'kinase inhibitor' class, including a medicine called imatinib.

GIST is rare, and Qinlock was designated an 'orphan medicine' (a medicine used in rare diseases) on 12 October 2017.

Qinlock contains the active substance ripretinib.

Expand section

Collapse section

## How is Qinlock used?

Qinlock is available as tablets to be taken by mouth and can only be obtained with a prescription. Treatment should be started by a doctor experienced in the treatment of cancer.

The recommended dose is 150 mg per day, taken at the same time each day. Treatment may be paused or the dose reduced to 100 mg per day if side effects are not tolerable. Treatment should continue as long as the patient benefits from it, or the side effects become unmanageable.

For more information about using Qinlock, see the package leaflet or contact your doctor or pharmacist.

## How does Qinlock work?

The active substance in Qinlock, ripretinib, is one of a group of cancer medicines called receptor tyrosine kinase inhibitors. It works by blocking the activity of receptors (targets) called KIT and PDGFRA on the surface of cancer cells. These receptors help to control cell growth but can be abnormal (mutated) in GIST cancer cells, causing the cells to multiply uncontrollably. By blocking the action of the abnormal receptors, the medicine is expected to help to slow down the tumour growth.

## What benefits of Qinlock have been shown in studies?

Qinlock was shown to be effective at treating GIST in a study involving 129 patients who had been previously treated with, or could not tolerate, at least three other cancer medicines. The study showed that patients treated with Qinlock lived on average for 27.6 weeks without their disease getting worse, compared with 4.1 weeks for patients given placebo (a dummy treatment).

## What are the risks associated with Qinlock?

The most common side effects with Qinlock (which may affect more than 1 in 4 people) are tiredness, hair loss, nausea (feeling sick), muscle pain, constipation, diarrhoea, palmar-plantar erythrodysaesthesia syndrome (PPES, rash and numbness on the palms and soles), weight loss and vomiting.

For the full list of side effects and restriction of Qinlock, see the package leaflet.

## Why is Qinlock authorised in the EU?

Qinlock was shown to be effective at slowing down the progress of the disease in patients with GIST who had been treated with at least three other medicines. Qinlock was shown to have a favourable safety profile with manageable side effects.

The European Medicines Agency therefore decided that Qinlock's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Qinlock?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Qinlock have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Qinlock are continuously monitored. Suspected side effects reported with Qinlock are carefully evaluated and any necessary action taken to protect patients.

## Other information about Qinlock

Qinlock received a marketing authorisation valid throughout the EU on 18 November 2021.

Qinlock : EPAR - Medicine overview

Reference Number: EMA/604575/2021

English (EN) (108.28 KB - PDF)

**First published:** 23/11/2021

[View](/en/documents/overview/qinlock-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-623)

български (BG) (142.38 KB - PDF)

**First published:**

23/11/2021

[View](/bg/documents/overview/qinlock-epar-medicine-overview_bg.pdf)

español (ES) (116.38 KB - PDF)

**First published:**

23/11/2021

[View](/es/documents/overview/qinlock-epar-medicine-overview_es.pdf)

čeština (CS) (139.16 KB - PDF)

**First published:**

23/11/2021

[View](/cs/documents/overview/qinlock-epar-medicine-overview_cs.pdf)

dansk (DA) (115.99 KB - PDF)

**First published:**

23/11/2021

[View](/da/documents/overview/qinlock-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.14 KB - PDF)

**First published:**

23/11/2021

[View](/de/documents/overview/qinlock-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.24 KB - PDF)

**First published:**

23/11/2021

[View](/et/documents/overview/qinlock-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.8 KB - PDF)

**First published:**

23/11/2021

[View](/el/documents/overview/qinlock-epar-medicine-overview_el.pdf)

français (FR) (107.67 KB - PDF)

**First published:**

23/11/2021

[View](/fr/documents/overview/qinlock-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.4 KB - PDF)

**First published:**

23/11/2021

[View](/hr/documents/overview/qinlock-epar-medicine-overview_hr.pdf)

italiano (IT) (115.2 KB - PDF)

**First published:**

23/11/2021

[View](/it/documents/overview/qinlock-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.94 KB - PDF)

**First published:**

23/11/2021

[View](/lv/documents/overview/qinlock-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.91 KB - PDF)

**First published:**

23/11/2021

[View](/lt/documents/overview/qinlock-epar-medicine-overview_lt.pdf)

magyar (HU) (137.38 KB - PDF)

**First published:**

23/11/2021

[View](/hu/documents/overview/qinlock-epar-medicine-overview_hu.pdf)

Malti (MT) (139.4 KB - PDF)

**First published:**

23/11/2021

[View](/mt/documents/overview/qinlock-epar-medicine-overview_mt.pdf)

Nederlands (NL) (107.85 KB - PDF)

**First published:**

23/11/2021

[View](/nl/documents/overview/qinlock-epar-medicine-overview_nl.pdf)

polski (PL) (140.95 KB - PDF)

**First published:**

23/11/2021

[View](/pl/documents/overview/qinlock-epar-medicine-overview_pl.pdf)

português (PT) (116.72 KB - PDF)

**First published:**

23/11/2021

[View](/pt/documents/overview/qinlock-epar-medicine-overview_pt.pdf)

română (RO) (137.15 KB - PDF)

**First published:**

23/11/2021

[View](/ro/documents/overview/qinlock-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.06 KB - PDF)

**First published:**

23/11/2021

[View](/sk/documents/overview/qinlock-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.43 KB - PDF)

**First published:**

23/11/2021

[View](/sl/documents/overview/qinlock-epar-medicine-overview_sl.pdf)

Suomi (FI) (104.21 KB - PDF)

**First published:**

23/11/2021

[View](/fi/documents/overview/qinlock-epar-medicine-overview_fi.pdf)

svenska (SV) (115.23 KB - PDF)

**First published:**

23/11/2021

[View](/sv/documents/overview/qinlock-epar-medicine-overview_sv.pdf)

Qinlock : EPAR - Risk-management-plan summary

English (EN) (248.59 KB - PDF)

**First published:** 23/11/2021

**Last updated:** 30/08/2023

[View](/en/documents/rmp-summary/qinlock-epar-risk-management-plan-summary_en.pdf)

## Product information

Qinlock : EPAR - Product information

English (EN) (295.48 KB - PDF)

**First published:** 23/11/2021

**Last updated:** 15/10/2025

[View](/en/documents/product-information/qinlock-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-165)

български (BG) (420.91 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/bg/documents/product-information/qinlock-epar-product-information_bg.pdf)

español (ES) (287.97 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/es/documents/product-information/qinlock-epar-product-information_es.pdf)

čeština (CS) (379.27 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/cs/documents/product-information/qinlock-epar-product-information_cs.pdf)

dansk (DA) (284.49 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/da/documents/product-information/qinlock-epar-product-information_da.pdf)

Deutsch (DE) (305.19 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/de/documents/product-information/qinlock-epar-product-information_de.pdf)

eesti keel (ET) (285.41 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/et/documents/product-information/qinlock-epar-product-information_et.pdf)

ελληνικά (EL) (526.14 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/el/documents/product-information/qinlock-epar-product-information_el.pdf)

français (FR) (301.38 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/fr/documents/product-information/qinlock-epar-product-information_fr.pdf)

hrvatski (HR) (364.65 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/hr/documents/product-information/qinlock-epar-product-information_hr.pdf)

íslenska (IS) (315.78 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/is/documents/product-information/qinlock-epar-product-information_is.pdf)

italiano (IT) (293.12 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/it/documents/product-information/qinlock-epar-product-information_it.pdf)

latviešu valoda (LV) (360.6 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/lv/documents/product-information/qinlock-epar-product-information_lv.pdf)

lietuvių kalba (LT) (374.54 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/lt/documents/product-information/qinlock-epar-product-information_lt.pdf)

magyar (HU) (407.94 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/hu/documents/product-information/qinlock-epar-product-information_hu.pdf)

Malti (MT) (373.13 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/mt/documents/product-information/qinlock-epar-product-information_mt.pdf)

Nederlands (NL) (303.84 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/nl/documents/product-information/qinlock-epar-product-information_nl.pdf)

norsk (NO) (320.68 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/no/documents/product-information/qinlock-epar-product-information_no.pdf)

polski (PL) (390.8 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/pl/documents/product-information/qinlock-epar-product-information_pl.pdf)

português (PT) (322.93 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/pt/documents/product-information/qinlock-epar-product-information_pt.pdf)

română (RO) (371.47 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/ro/documents/product-information/qinlock-epar-product-information_ro.pdf)

slovenčina (SK) (382.33 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/sk/documents/product-information/qinlock-epar-product-information_sk.pdf)

slovenščina (SL) (369.28 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/sl/documents/product-information/qinlock-epar-product-information_sl.pdf)

Suomi (FI) (290.18 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/fi/documents/product-information/qinlock-epar-product-information_fi.pdf)

svenska (SV) (307.18 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

15/10/2025

[View](/sv/documents/product-information/qinlock-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000284381 11/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Qinlock : EPAR - All authorised presentations

English (EN) (39.04 KB - PDF)

**First published:** 23/11/2021

[View](/en/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-231)

български (BG) (53 KB - PDF)

**First published:**

23/11/2021

[View](/bg/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.86 KB - PDF)

**First published:**

23/11/2021

[View](/es/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.82 KB - PDF)

**First published:**

23/11/2021

[View](/cs/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.87 KB - PDF)

**First published:**

23/11/2021

[View](/da/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (47 KB - PDF)

**First published:**

23/11/2021

[View](/de/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.13 KB - PDF)

**First published:**

23/11/2021

[View](/et/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61.6 KB - PDF)

**First published:**

23/11/2021

[View](/el/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_el.pdf)

français (FR) (46.37 KB - PDF)

**First published:**

23/11/2021

[View](/fr/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.95 KB - PDF)

**First published:**

23/11/2021

[View](/hr/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (64.38 KB - PDF)

**First published:**

23/11/2021

[View](/is/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.75 KB - PDF)

**First published:**

23/11/2021

[View](/it/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.17 KB - PDF)

**First published:**

23/11/2021

[View](/lv/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.88 KB - PDF)

**First published:**

23/11/2021

[View](/lt/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.44 KB - PDF)

**First published:**

23/11/2021

[View](/hu/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.64 KB - PDF)

**First published:**

23/11/2021

[View](/mt/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.75 KB - PDF)

**First published:**

23/11/2021

[View](/nl/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (42.78 KB - PDF)

**First published:**

23/11/2021

[View](/no/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_no.pdf)

polski (PL) (55.88 KB - PDF)

**First published:**

23/11/2021

[View](/pl/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.22 KB - PDF)

**First published:**

23/11/2021

[View](/pt/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.83 KB - PDF)

**First published:**

23/11/2021

[View](/ro/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.36 KB - PDF)

**First published:**

23/11/2021

[View](/sk/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.14 KB - PDF)

**First published:**

23/11/2021

[View](/sl/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.67 KB - PDF)

**First published:**

23/11/2021

[View](/fi/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.1 KB - PDF)

**First published:**

23/11/2021

[View](/sv/documents/all-authorised-presentations/qinlock-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Qinlock Active substance ripretinib International non-proprietary name (INN) or common name ripretinib Therapeutic area (MeSH) Gastrointestinal Stromal Tumors Anatomical therapeutic chemical (ATC) code L01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

## Authorisation details

EMA product number EMEA/H/C/005614

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Deciphera Pharmaceuticals (Netherlands) B.V.

Atrium Building Floor 4th

Opinion adopted 16/09/2021 Marketing authorisation issued 18/11/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Qinlock : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (168.88 KB - PDF)

**First published:** 15/10/2025

[View](/en/documents/procedural-steps-after/qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Qinlock : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (167.05 KB - PDF)

**First published:** 13/12/2021

**Last updated:** 15/10/2025

[View](/en/documents/procedural-steps-after/qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Qinlock-H-C-PSUSA-00010962-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/242978/2023

English (EN) (124.68 KB - PDF)

**First published:** 30/05/2023

[View](/en/documents/scientific-conclusion/qinlock-h-c-psusa-00010962-202205-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Qinlock : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/555164/2021

English (EN) (4.31 MB - PDF)

**First published:** 23/11/2021

**Last updated:** 23/11/2021

[View](/en/documents/assessment-report/qinlock-epar-public-assessment-report_en.pdf)

Qinlock : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000057360

English (EN) (293.6 KB - PDF)

**First published:** 23/11/2021

[View](/en/documents/orphan-maintenance-report/qinlock-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Qinlock

Adopted

Reference Number: EMA/CHMP/338054/2021

English (EN) (128.12 KB - PDF)

**First published:** 17/09/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-qinlock_en.pdf)

#### News on Qinlock

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

#### More information on Qinlock

- [EU/3/17/1936 - orphan designation for treatment of gastrointestinal stromal tumours](/en/medicines/human/orphan-designations/eu-3-17-1936)

**This page was last updated on** 15/10/2025

## Share this page

[Back to top](#main-content)